Fig. 9
A model for synergistic interaction between apigenin and ABT-263 in cells with EGFR activating mutation. Apigenin upregulated the expression of Noxa in EGFRm tumor cells by targeting the AKT-FoxO3a pathway and inhibited ERK, thereby synergizing with ABT-263 to suppress tumor cell growth and proliferation in vitro and in vivo